| Primary |
| Product Used For Unknown Indication |
42.4% |
| Schizophrenia |
27.3% |
| Schizoaffective Disorder |
7.0% |
| Bipolar Disorder |
4.8% |
| Drug Use For Unknown Indication |
3.8% |
| Psychotic Disorder |
3.5% |
| Schizophrenia, Paranoid Type |
1.8% |
| Depression |
1.5% |
| Ill-defined Disorder |
1.3% |
| Anxiety |
1.0% |
| Hypertension |
0.9% |
| Diabetes Mellitus |
0.7% |
| Sleep Disorder |
0.7% |
| Bipolar I Disorder |
0.7% |
| Insomnia |
0.7% |
| Drug Therapy |
0.5% |
| Agitation |
0.4% |
| Affective Disorder |
0.4% |
| Extrapyramidal Disorder |
0.4% |
| Convulsion |
0.4% |
|
| Drug Dose Omission |
15.5% |
| Weight Increased |
9.8% |
| Drug Ineffective |
8.2% |
| Inappropriate Schedule Of Drug Administration |
6.9% |
| Injection Site Nodule |
6.8% |
| Product Quality Issue |
5.2% |
| Psychotic Disorder |
5.2% |
| Injection Site Pain |
4.9% |
| Galactorrhoea |
4.9% |
| Incorrect Dose Administered |
3.9% |
| Injection Site Mass |
3.7% |
| Schizophrenia |
3.3% |
| Therapeutic Response Decreased |
3.2% |
| Treatment Noncompliance |
2.9% |
| Hospitalisation |
2.9% |
| Blood Prolactin Increased |
2.8% |
| Tremor |
2.6% |
| Condition Aggravated |
2.5% |
| Device Leakage |
2.5% |
| Underdose |
2.4% |
|
| Secondary |
| Schizophrenia |
29.2% |
| Product Used For Unknown Indication |
23.2% |
| Psychotic Disorder |
10.3% |
| Bipolar Disorder |
9.2% |
| Schizoaffective Disorder |
8.3% |
| Depression |
4.0% |
| Schizophrenia, Paranoid Type |
2.0% |
| Delusion |
1.8% |
| Anxiety |
1.3% |
| Hypertension |
1.2% |
| Bipolar I Disorder |
1.2% |
| Drug Use For Unknown Indication |
1.2% |
| Agitation |
1.1% |
| Sleep Disorder |
1.1% |
| Ill-defined Disorder |
0.9% |
| Autism |
0.8% |
| Hallucination |
0.8% |
| Paranoia |
0.8% |
| Insomnia |
0.7% |
| Drug Therapy |
0.7% |
|
| Inappropriate Schedule Of Drug Administration |
11.3% |
| Weight Increased |
9.7% |
| Drug Ineffective |
8.4% |
| Psychotic Disorder |
6.9% |
| Drug Dose Omission |
6.2% |
| Product Quality Issue |
5.7% |
| Treatment Noncompliance |
5.7% |
| Schizophrenia |
4.9% |
| Galactorrhoea |
4.8% |
| Hospitalisation |
4.4% |
| Tardive Dyskinesia |
3.8% |
| Therapeutic Response Decreased |
3.8% |
| Off Label Use |
3.7% |
| Incorrect Dose Administered |
3.5% |
| Injection Site Pain |
3.2% |
| Tremor |
3.2% |
| Injection Site Nodule |
3.0% |
| Condition Aggravated |
2.8% |
| Akathisia |
2.4% |
| Injection Site Mass |
2.4% |
|
| Concomitant |
| Bipolar Disorder |
19.0% |
| Schizophrenia |
15.8% |
| Bipolar I Disorder |
13.9% |
| Medical Diet |
7.6% |
| Adverse Drug Reaction |
5.1% |
| Sleep Disorder |
4.4% |
| Affective Disorder |
3.8% |
| Product Used For Unknown Indication |
3.2% |
| Blood Cholesterol |
2.5% |
| Cardiac Disorder |
2.5% |
| Cardiovascular Disorder |
2.5% |
| Diabetes Mellitus |
2.5% |
| Erectile Dysfunction |
2.5% |
| Neuropathy Peripheral |
2.5% |
| Scoliosis |
2.5% |
| Stress |
2.5% |
| Delusion |
1.9% |
| Depression |
1.9% |
| Hallucination |
1.9% |
| Hyperlipidaemia |
1.3% |
|
| Urine Output Increased |
18.2% |
| Drug Ineffective |
12.1% |
| Schizophrenia |
9.1% |
| Leukopenia |
6.1% |
| Neuropathy Peripheral |
6.1% |
| Respiratory Arrest |
6.1% |
| Burning Sensation |
3.0% |
| Catatonia |
3.0% |
| Completed Suicide |
3.0% |
| Diabetes Mellitus |
3.0% |
| Erectile Dysfunction |
3.0% |
| General Physical Health Deterioration |
3.0% |
| Granulocytopenia |
3.0% |
| Headache |
3.0% |
| Hospitalisation |
3.0% |
| Loss Of Consciousness |
3.0% |
| Metabolic Disorder |
3.0% |
| Neoplasm Malignant |
3.0% |
| Neutropenia |
3.0% |
| Nocturnal Dyspnoea |
3.0% |
|
